Burning Rock Biotech (BNR) Operating Income (2019 - 2026)

Burning Rock Biotech (BNR) has reported Operating Income for 8 consecutive years, with -$2.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Income fell 30.48% year-over-year to -$2.7 million; the TTM figure through Mar 2026 stood at -$8.3 million (up 75.6% YoY), while the FY2025 annual figure was -$7.8 million, up 83.99% from the prior year.
• Operating Income came in at -$2.7 million for Q1 2026 at Burning Rock Biotech, down from -$1.7 million in the prior quarter.
• The five-year high for Operating Income was -$1.6 million in Q2 2025, with the low at -$41.5 million in Q1 2022.
• Average Operating Income over 5 years is -$17.6 million, with a median of -$17.4 million recorded in 2024.
• Across the five-year window, Operating Income slumped 58.08% in 2022 and soared 89.51% in 2025, its largest moves.
• Year by year, Operating Income stood at -$31.5 million in 2022, then increased by 25.69% to -$23.4 million in 2023, then soared by 52.09% to -$11.2 million in 2024, then soared by 84.67% to -$1.7 million in 2025, then sank by 58.69% to -$2.7 million in 2026.
• According to Business Quant data, Operating Income over the past three periods registered -$2.7 million, -$1.7 million, and -$2.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.